Showing 5471-5480 of 7864 results for "".
- Study Links Skin Microbiota and AD Alleviation via Melatoninhttps://practicaldermatology.com/news/study-links-skin-microbiota-and-ad-alleviation-melatonin/2468664/A new study published in the Journal of Allergy and Clinical Immunology indicates melatonin has been shown to reduce atopic dermatitis (AD) symptoms by altering skin microbiota composition, with short-chain fatty acids (SCFAs) such as propionic acid playing a key role in this process. Alth
- Panel Agrees on Key Recommendations for Oral Minoxidil Usehttps://practicaldermatology.com/news/panel-agrees-key-recommendations-oral-minoxidil-use/2468659/A new international consensus statement offers guidance on the off-label use of low-dose oral minoxidil (LDOM) for managing hair loss. The
- FDA Greenlights BIMZELX for Chronic Hidradenitis Suppurativahttps://practicaldermatology.com/news/fda-greenlights-bimzelx-chronic-hidradenitis-suppurativa/2468635/The Food and Drug Administration (FDA) has approved BIMZELX® (bimekizumab-bkzx) for adults with moderate-to-severe hidradenitis suppurativa (HS), making it the first treatment to selectively inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL-17F). According to a press release f
- Xylazine Wounds: Chronicity Linked to Necrosishttps://practicaldermatology.com/news/xylazine-wounds-chronicity-linked-necrosis/2468631/Xylazine-associated wounds frequently present on extremities with necrotic wound beds and increase in severity with chronicity, according to a systematic case series published in JAMA Dermatology. The case series was conducted across three academic hospitals looking at clinical characteris
- Analyses: Ruxolitinib Cream Reduces AD Symptom Burden in 12 Hourshttps://practicaldermatology.com/news/analyses-ruxolitinib-cream-reduces-ad-symptom-burden-12-hours/2468615/Ruxolitinib cream significantly reduced skin pain and improved patient-reported outcomes (PROs) in individuals with mild-to-moderate atopic dermatitis (AD), with improvements sustained over 52 weeks, according to data from the TRuE-AD1 and TRuE-AD2 studies. Researchers the results publishi
- Botanix Announces Expanded Payer Coverage for Sofdrahttps://practicaldermatology.com/news/botanix-announces-expanded-payer-coverage-sofdra/2468602/Botanix announced today that Ascent Health, second largest Payer (insurer) organization in the US, will now cover Sofdra™ (sofpironium) topical gel, 12.45%, for the treatment of primary axillary hyperhydrosis. According to a press release from Botanix, Ascent represents approximat
- Zasocitinib Effective in Moderate to Severe Psoriasis: Analysishttps://practicaldermatology.com/news/study-zasocitinib-effective-moderate-severe-psoriasis/2468601/Results from a recent placebo-controlled trial of zasocitinib showed promise in improving skin clearance for patients with moderate to severe plaque psoriasis. The phase 2b study, conducted across multiple centers in the United States and Canada, included 259 patients treated over 12 week
- Roflumilast Cream 0.15% Receives Glamour's Best Eczema Product Award for 2024https://practicaldermatology.com/news/roflumilast-cream-015-receives-glamours-best-eczema-product-award-2024/2468585/Arcutis Biotherapeutics announced today that ZORYVE® (roflumilast) cream 0.15% has been named Best Eczema Product by Glamour magazine in its 2024 Health and Wellness Awards. The cream, which is the first once-daily FDA-approved topical treatment specifically indicated for mild to
- Study: Botanical Gummies Show Promise for Thinning Hairhttps://practicaldermatology.com/news/study-botanical-gummies-show-promise-thinning-hair/2468582/A recent 6-month study found that a daily gummy supplement with B vitamins, zinc, and botanicals improved hair density, strength, and perceived hair quality in women with thinning hair. Researchers for the double-blind, placebo-controlled trial included 65 healthy female participants aged
- Study Links Severe AD With Need for Surgery in Glaucoma Patientshttps://practicaldermatology.com/news/study-links-severe-ad-need-surgery-glaucoma-patients/2468562/Patients suffering from both severe atopic dermatitis (AD) and glaucoma are increasingly likely to need surgical intervention for the glaucoma depending on the severity of their AD, according to a new Journal of Glaucoma study. “Association of Atopic Dermatitis and Risk of Glaucoma Surgery